Semi-Annual Consolidated Statement Of Cash Flows

KYORIN Pharmaceutical Co., Ltd. - Filing #7298873

Concept As at
2024-09-30
2024-04-01 to
2024-09-30
As at
2024-03-31
As at
2023-09-30
2023-04-01 to
2023-09-30
As at
2023-03-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
3,855,000,000 JPY
9,880,000,000 JPY
Interest and dividends received
256,000,000 JPY
268,000,000 JPY
Interest paid
-54,000,000 JPY
-33,000,000 JPY
Income taxes paid
-412,000,000 JPY
-1,751,000,000 JPY
Net cash provided by (used in) operating activities
3,379,000,000 JPY
8,364,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-4,637,000,000 JPY
-937,000,000 JPY
Proceeds from sale of property, plant and equipment
42,000,000 JPY
0 JPY
Purchase of investment securities
JPY
0 JPY
Other, net
-215,000,000 JPY
-475,000,000 JPY
Net cash provided by (used in) investing activities
-5,235,000,000 JPY
327,000,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
14,000,000,000 JPY
JPY
Repayments of long-term borrowings
-100,000,000 JPY
-100,000,000 JPY
Dividends paid
-1,855,000,000 JPY
-1,853,000,000 JPY
Net cash provided by (used in) financing activities
1,987,000,000 JPY
-2,020,000,000 JPY
Other, net
-57,000,000 JPY
-66,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
0 JPY
95,000,000 JPY
Net increase (decrease) in cash and cash equivalents
130,000,000 JPY
6,767,000,000 JPY
Cash and cash equivalents
14,017,000,000 JPY
13,886,000,000 JPY
25,584,000,000 JPY
18,816,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.